检索结果-南通市图书馆

The Chinese-German Journal of Clinical Oncology 2014年第9期13卷 417-421页

作者： Abeer A.Mahmoud Eman A.El-Sharawy Mohamed M.El-Bassiouny ramy r.ghali Clinical Oncology Department Faculty of Medicine Ain Shams University

Objective: Maximum androgen blockade(MAB), consisting of an antiandrogen plus either a luteinizing hormonereleasing hormone agonist(LHrHA) or orchiectomy, is a standard care for patients with prostate cancer. Although, clinical trial results have been equivocal, none has shown a significant advantage in favor of MAB over castration alone in metastatic prostate cancer and MAB has been the subject of considerable controversy. The aim of this study was to compare MAB(orchiectomy or LHrHA "Goserelin") and anti-androgen "Bicalutamide" with castration alone(orchiectomy or LHrHA) in previously untreated metastatic prostate cancer patients. Methods: Hundred eligible patients with adequate performance status and adequate hematologic, hepatic and renal functions were included. MAB arm, fifty patients underwent castration either surgically by orchiectomy or medically by receiving Goserelin(3.6 mg) depot, which was injected subcutaneously every 28 days plus bicalutamide 50 mg once daily. Castration alone arm, fifty patients underwent castration alone either surgically by orchiectomy or medically by receiving Goserelin(3.6 mg) depot. results: During the period from January 2011 to January 2013, with a median follow up of 18 months(range 6 to 24 months), there were eight deaths(16%), in MAB arm and ten deaths(20%) in castration alone arm. At three months, there were 35 patients(70%) with prostate specific antigen(PSA) normalization(≤ 4 mg/dL) in MAB arm versus 17 patients(34%) with PSA normalization in castration alone arm(P = 0.001). The median progression free survival(PFS) times were 22.18 months(95% CI, 19.7 to 24.2 months) for MAB arm versus 22 months in castration alone arm(95% CI, 18 to 25.9 months; P = 0.045). The survival rates for MAB arm were 82% at 18 months and 70.6% at 24 months versus 78.7% at 18 months and 75.1% at 24 months in castration alone arm(P > 0.05). The median overall survival(OS) was not reached in either arm. Both hematological and non-hematological to

关键词：前列腺癌抗雄激素转移性去势人与生物圈计划促黄体激素释放激素阉割手术 MAB

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

吉西他滨联合顺铂治疗恶性胸膜间皮瘤:一个机构的研究经验(英文)

引用

The Chinese-German Journal of Clinical Oncology 2013年第5期12卷 213-218页

作者： ramy r. ghali Sherif Abdelwahab Mohamed E. L. Bassiuony Ayman I. Kamel Hussein Shalaby Dina N. K. Boulos Clinical Oncology Department Ain Shams University radiodiagnosis Department Cairo University Chest Department Abbassia Chest Hospital Community Environmental and Occupational Medicine DepartmentAin Shams University

Objective:The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma (MPM). Methods:Thirty-three eligible patients with histologically proven advanced MPM with ECOG PS of ≤ 2 and had adequate liver and kidney functions received gemcitabine (1000 mg/m 2 ) on days 1 and 8 combined with cisplatin (80 mg/m 2 ) on day 1. results:The majority of the study group were males and constituted 87.9% (n = 29), while females constituted 12.1% (n = 4). The median age was 52 years and ranged from 37 to 69 years. regarding SWOG performance status, 5 patients were PS 0, 21 patients were PS 1 and 7 patients were PS 2. regarding pathological subtypes, epithelial histology represented 84.8% of the study (n = 28) while sarcomatoid type represented 6% (n = 2) and biphasic type accounted for 9% (n = 3). regarding staging according to IMIG staging system, 12.1% of patients were stage II, 54.5% were stage III and 33.3% were stage IV. Only one patient (3%) had attained a complete response, 18 patients (54.5%) showed partial response, 12 patients (36.4%) showed stationary disease, while 2 patients (6.1%) showed progressive disease. The correlation between response rate obtained and PS was statistically significant (P = 0.029). After a median follow-up of 14.4 months, the median survival time was 20.3 months (95% CI:14.58-26.01 months) and the progression free survival time was 11.8 months (95% CI:10.76-12.83 months) Conclusion:The combination of gemcitabine and cisplatin is an active and safe treatment in patients with MPM. Further larger comparative studies are warranted to document this finding.

关键词： MPM 顺铂治疗恶性晚期机构膜生存时间

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：